The role of the hippocampo-prefrontal cortex system in phencyclidine-induced psychosis: A model for schizophrenia

Journal of Physiology Paris

Volumn 107, Issue 6, 2013, Pages 434-440

  Jodo, Eiichi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Animal models; Electrophysiology; Hippocampus; MK801; NMDA; PCP; Phencyclidine; Prefrontal cortex; Schizophrenia

Indexed keywords

DIZOCILPINE; DOPAMINE 2 RECEPTOR; PHENCYCLIDINE;

BINDING AFFINITY; BRAIN NERVE CELL; CELL ACTIVATION; CONNECTOME; DISEASE MODEL; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; GABAERGIC TRANSMISSION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; HYPERLOCOMOTION; MEDIAL PREFRONTAL CORTEX; MOLECULAR DYNAMICS; MOTOR DYSFUNCTION; NERVE CELL STIMULATION; NERVE PROJECTION; NEUROPATHOLOGY; NONHUMAN; PHENCYCLIDINE INDUCED PSYCHOSIS; PREFRONTAL CORTEX; PSYCHOSOCIAL WITHDRAWAL; PYRAMIDAL NERVE CELL; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; STEREOTYPY;

AMPA; ANIMAL MODELS; ELECTROPHYSIOLOGY; GABA; HIPPOCAMPUS; MD; MEDIAL PREFRONTAL CORTEX; MEDIODORSAL NUCLEUS OF THE THALAMUS; MK801; MPFC; N-METHYL-D-ASPARTATE; NMDA; PCP; PFC; PHENCYCLIDINE; PREFRONTAL CORTEX; SCHIZOPHRENIA; Α-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; Γ-AMINOBUTYLIC ACID;

ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; PHENCYCLIDINE; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; RATS; SCHIZOPHRENIA;

EID: 84888040441     PISSN: 09284257     EISSN: 17697115     Source Type: Journal    
DOI: 10.1016/j.jphysparis.2013.06.002     Document Type: Review

References (85)

1. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 1998, 18:5545-5554.
2. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Rev. 2000, 31:302-312.
3. Al-Amin H.A., Shannon Weickert C., Weinberger D.R., Lipska B.K. Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biol. Psychiatry 2001, 49:528-539.
4. Angrist B., Sathananthan G., Wilk S. Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 1974, 11:13-23.
5. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 1983, 79:565-575.
6. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Compr. Psychiatry 1961, 2:269-280.
7. Balster, R. L., Wessinger, W. D., 1983. Central nervous system depressant effects of phencyclidine. In: Kamenka J. M., et al. (Ed.), Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications. Ann Arbor, MI: NPP Books. pp. 291-309.
8. Berwaerts J., Cleton A., Rossenu S., Talluri K., Remmerie B., Janssens L., Boomm S., Kramer M., Eerdekens M. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J. Psychopharmacol. 2010, 24:1011-1018.
9. Brown R.W., Maple A.M., Perna M.K., Sheppard A.B., Cope Z.A., Kostrzewa R.M. Schizophrenia and substance abuse comorbidity: nicotine addiction and the neonatal quinpirole model. Dev. Neurosci. 2012, 34:140-151.
10. Bubser M., De Brabander J.M., Timmerman W., Freenstra M.G.P., Erdtsieck-Ernste E.B., Rinnens A., Van Uum J.F.M., Westerink B.H.C. Disinhibition of the mediodorsal thalamus induces Fos-like immunoreactivity in both pyramidal and GABA-containing neurons in the medial prefrontal cortex of rats, but does not affect prefrontal levels of GABA. Synapse 1998, 30:156-165.
11. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1:179-186.
12. Carlsson M., Carlsson A. The NMDA antagonist MK801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 1989, 75:221-226.
13. Carrier N., Kabbaj M. Sex differences in social interaction behaviors in rats are mediated by extracellular signal-regulated kinase 2 expression in the medial prefrontal cortex. Neuroscience 2012, 212:86-92.
14. Castellani S., Adams P.M. Effects of dopaminergic drugs on phencyclidine-induced behavior in the rat. Neuropharmacology 1981, 20:371-374.
15. Ceci A., French E.D. Phencyclidine-induced activation of ventral tegmental A10 dopamine neurons is differentially affected by lesions of the nucleus accumbens and medial prefrontal cortex. Life Sci. 1989, 45:637-646.
16. 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol. Psychiatry 1991, 29:629-634.
17. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
18. DeFelipe J., Farinas I. The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs. Prog. Neurobiol. 1992, 39:563-607.
19. Dilmore J.G., Johnson J.W. Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine. Biophys. J. 1998, 75:1801-1816.
20. Domino, E. F., Luby, E., 1981. Abnormal mental states induced by phencyclidine as a model of schizophrenia, PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor, NPP Books.
21. Elliott R., Lythe K., Lee R., McKie S., Juhasz G., Thomas E.J., Downey D., Deakin J.F., Anderson I.M. Reduced medial prefrontal responses to social interaction images in remitted depression. Arch. Gen. Psychiatry 2012, 69:37-45.
22. Fessler R.G., Sturgeon R.D., Meltzer H.Y. Effects of phencyclidine and methylphenidate on d-amphetamine-induced behaviors in reserpine pretreated rats. Pharmacol. Biochem. Behav. 1980, 13:835-842.
23. Floresco S.B., Grace A.A. Gating of hippocampal-evoked activity in prefrontal cortical neurons by inputs from the mediodorsal thalamus and ventral tegmental area. J. Neurosci. 2003, 23:3930-3943.
24. Garver D.L., Zemlan F., Hirschowitz J., Hitzemann R., Mavroidis M.L. Dopamine and non-dopamine psychoses. Psychopharmacology (Berl) 1984, 84:138-140.
25. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 2000, 57:65-73.
26. Gratton A., Hoffer B.J., Freedman R. Electrophysiological effects of phencyclidine in the medial prefrontal cortex of the rat. Neuropharmacology 1987, 26:1275-1283.
27. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001, 11:569-577.
28. Groenewegen H.J., Berendse H.W., Wolters J.G., Lohman A.H.M. The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and the amygdala: evidence for a parallel organization. Prog. Brain Res. 1990, 85:95-118.
29. Grunze H.C., Rainie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., Greene R.W. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 1996, 16:2034-2043.
30. 2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J. Neurosci. 2000, 20:RC106.
31. Haggerty G.C., Forney R.B., Johnson J.M. The effect of a single administration of phencyclidine on behavior in the rat over a 21-day period. Toxicol. Appl. Pharmacol. 1984, 75:444-453.
32. Hirayasu Y., Shenton M.E., Salisbury D.F., McCarley R.W. Hippocampal and superior temporal gyrus volume in first-episode schizophrenia. Arch. Gen. Psychiatry 2000, 57:618-619.
33. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 2007, 27:11496-11500.
34. Homayoun H., Jackson M.E., Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J. Neurophysiol. 2005, 93:1989-2001.
35. Honey C.R., Miljkovic Z., MacDonald J.F. Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci. Lett. 1985, 61:135-139.
36. Hoover W.B., Vertes R.P. Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat. Brain Struct. Funct. 2007, 212:149-179.
37. Huettner J.E., Bean B.P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl. Acad. Sci. USA 1988, 85:1307-1311.
38. Itil T., Keskiner A., Kiremicti N., Holden J.M.C. Effect of phencyclidine in chronic schizophrenia. Can. Psychiatr. Assoc. J. 1967, 12:209-212.
39. Jackson M.E., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. USA 2004, 101:8467-8472.
40. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
41. Jay T.M., Witter M.P. Distribution of hippocampal CA1 and subicular efferents in the prefrontal cortex of te rat studied by means of anterograde tranport of Phaseolus vulgaris-Leucoagglutinin. J. Comp. Neurol. 1991, 313:574-586.
42. Jay T.M., Thierry A.M., Wiklund L., Glowinski J. Excitatory amino acid pathway from the hippocampus to the prefrontal cortex. Contribution of AMPA receptors in hippoocampo-prefrontal cortex transmission. Eur. J. Neurosci. 1992, 4:1285-1295.
43. Jentsch J.D., Dazzi L., Chhatwal J.P., Verrico C.D., Roth R.H. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci. Lett. 1998, 258:175-178.
44. Jessen F., Scheef L., Germeshausen L., Tawo Y., Kockler M., Kuhn K.U., Maier W., Schild H.H., Heun R. Reduced hippocampal activation during encoding and recognition of words in schizophrenia patients. Am. J. Psychiatry 2003, 160:1305-1312.
45. Jodo E., Suzuki Y., Takeuchi S., Niwa S., Kayama Y. Different effects of phencyclidine and methamphetamine on firing activity of medial prefrontal cortex neurons in freely moving rats. Brain Res. 2003, 962:226-231.
46. Jodo E., Suzuki Y., Katayama T., Hoshino K.Y., Takeuchi S., Niwa S., Kayama Y. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb. Cortex 2005, 15:663-669.
47. Jodo E., Katayama T., Okamoto M., Suzuki Y., Hoshino K., Kayama Y. Differences in responsiveness of mediodorsal thalamic and medial preforntal cortical neurons to social interaction and systemically administered phencyclidine in rats. Neuroscience 2010, 170:1153-1164.
48. Kamiyama H., Matsumoto M., Otani S., Kimura S.I., Shimamura K.I., Ishikawa S., Yanagawa Y., Togashi H. Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. Neuroscience 2011, 177:159-169.
49. Kargieman L., Santana N., Guadalupe M., Celada P., Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc. Natl. Acad. Sci. USA 2007, 104:14843-14848.
50. Katayama T., Jodo E., Suzuki Y., Hoshino K., Takeuchi S., Kayama Y. Activation of medial prefrontal cortex neurons by phencyclidine is mediated via AMPA/Kainate glutamate receptors in anesthetized rats. Neuroscience 2007, 150:442-448.
51. Koek W., Colpaert F.C., Woods J.H., Kamenka J.M. The phencyclidine (PCP) analog N-[1-(2-benzo(B)thiophenyl) cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801. J. Pharmacol. Exp. Ther. 1989, 250:1019-1027.
52. Konick L.C., Friedman L. Meta-analysis of thalamic size in schizophrenia. Biol. Psychiatry 2001, 49:28-38.
53. Kuroda M., Yokofujita J., Murakami K. An ultrastructural study of the neural circuits between the prefrontal cortex and the mediodorsal nucleus of the thalamus. Prog. Neurobiol. 1998, 54:417-458.
54. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 2005, 30:1883-1894.
55. Li Z., Boules M., Williams K., Peris J., Richelson E. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Res. 2010, 1311:28-36.
56. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drugs-sernyl. Am. Med. Assoc. Arch. Neurol. Psychiatry 1959, 81:363-369.
57. MacDonald J.F., Bartlett M.C., Mody I., Pahapill P., Reynolds J.N., Salter M.W., Schneiderman J.H., Pennefather P.S. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J. Physiol. 1991, 432:483-508.
58. Millan M.J., Brocco M., Gobert A., Joly F., Bervoets K., Rivet J.M., Neuman-Tancredi A., Audinot V., Maurel S. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP induced locomotion in the rat. Eur. J. Neurosci. 1999, 11:4419-4432.
59. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
60. Murase S., Mathé J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J. Neural Transm. Gen. Sect. 1993, 91:13-25.
61. Noda Y., Kamei H., Mamiya T., Furukawa H., Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 2000, 23:375-387.
62. Ogren S.O., Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 1994, 11:167-177.
63. Pawlowski L., Mathé J.M., Svensson T.H. Phencyclidine activates rat A10 dopamine neurons but reduces burst activity and causes regularization of firing. Acta Physiol. Scand. 1990, 139:529-530.
64. Sajdyk T.J., Shekhar A. Excitatory amino acid receptor antagonists block the cardiovascular and anxiety responses elicited by gamma-aminobutyric acidA receptor blockade in the basolateral amygdala of rats. J. Pharmacol. Exp. Ther. 1997, 283:969-977.
65. Sajdyk T.J., Johnson P.L., Leitermann R.J., Fitz S.D., Dietrich A., Morin M., Gehlert D.R., Urban J.H., Shekhar A. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J. Neurosci. 2008, 28:893-903.
66. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol. 1996, 7:3-23.
67. Schlemmer R.F., Jackson J.A., Preston K.L., Bederka J.P., Garver D.L., Davis J.M. Phencyclidine-induced stereotyped behavior in monkeys: antagonism by pimozide. Eur. J. Pharmacol. 1978, 52:379-384.
68. Schlumberger C., Schäfer D., Barberi C., Morè L., Nagel J., Pietraszek M., Schmidt W.J., Danysz W. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav. Pharmacol. 2009, 20:56-66.
69. Schobel S.A., Lewandowski N.M., Corcoran C.M., Moore H., Brown T., Malaspina D., Small S.A. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch. Gen. Psychiatry 2009, 66:938-946.
70. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
71. Sesack S.R., Bunney B.S. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study. J. Pharmacol. Exp. Ther. 1989, 248:1323-1333.
72. Shah A.A., Treit D. Excitotoxic lesions of the medial prefrontal cortex attenuate fear responses in the elevated-plus maze, social interaction and shock probe burying tests. Brain Res. 2003, 969:183-194.
73. Snell L.D., Yi S.J., Johnson K.M. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur. J. Pharmacol. 1988, 145:223-226.
74. Suzuki Y., Jodo E., Takeuchi S., Niwa S., Kayama Y. Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 2002, 114:769-779.
75. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. Schizophr. Res. 2008, 100:4-19.
76. Thornberg S.A., Saklad S.R. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy 1996, 16:82-93.
77. Truitt W.A., Sajdyk T.J., Dietrich A.D., Oberlin B., McDougle C.J., Shekhar A. From anxiety to autism: spectrum of abnormal social behaviors modeled by progressive disruption of inhibitory neuronal function in the basolateral amygdala in Wistar rats. Psychopharmacology (Berl.) 2007, 191:107-118.
78. Turgeon S.M., Hoge S.G. Prior exposure to phencyclidine decreases voluntary sucrose consumption and operant performance for food reward. Pharmacol. Biochem. Behav. 2003, 76:393-400.
79. Tye K.M., Mirzabekov J.J., Warden M.R., Ferenczi E.A., Tsai H.C., Finkelstein J., Kim S.Y., Adhikari A., Thompson K.R., Andalman A.S., Gunaydin L.A., Witten I.B., Deisseroth K. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-541.
80. Umemoto M., Takeichi T., Kurumiya S., Olds M.E. Selective neonatal depletion of dopamine has no effect on medial prefrontal cortex self-stimulation in the rat. Neurosci. Res. 1984, 1:295-307.
81. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 1996, 16:373-379.
82. Wall V.L., Fischer E.K., Bland S.T. Isolation rearing attenuates social interaction-induced expression of immediate early gene protein products in the medial prefrontal cortex of male and female rats. Physiol. Behav. 2012, 107:440-450.
83. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 1986, 43:114-124.
84. Yang C.R., Mogenson G.J. Dopaminergic modulation of cholinergic responses in rat medial prefrontal cortex: an electrophysiological study. Brain Res. 1990, 524:271-281.
85. Yonezawa Y., Kuroki T., Kawahara T., Tashiro N., Uchimura H. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur. J. Pharmacol. 1998, 341:45-56.